Avid Bioservices Q3 2023 Earnings Report $12.37 +0.01 (+0.08%) (As of 10:52 AM ET) Earnings HistoryForecast Avid Bioservices EPS ResultsActual EPS$0.03Consensus EPS -$0.08Beat/MissBeat by +$0.11One Year Ago EPSN/AAvid Bioservices Revenue ResultsActual Revenue$38.02 millionExpected Revenue$36.00 millionBeat/MissBeat by +$2.02 millionYoY Revenue GrowthN/AAvid Bioservices Announcement DetailsQuarterQ3 2023Date3/13/2023TimeN/AConference Call ResourcesPress ReleaseCDMO Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Avid Bioservices Earnings HeadlinesCraig-Hallum Sticks to Its Hold Rating for Avid Bioservices (CDMO)December 12, 2024 | markets.businessinsider.comAvid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024December 10, 2024 | globenewswire.com"X-Ray Vision" could find thousands of hidden market opportunitiesLet me show you how I trade with “X-Ray vision.” You see, most “trend” traders only use one trend filter when looking for an optimal buy signal. And that can be a big mistake because you can’t see if you’re in a “True Trend.” But my newest trading tool is designed to only target the best, most stable stocks… Using 3 trend filters… which are these green, yellow, and red lines.December 18, 2024 | Jack Carter Trading (Ad)Craig-Hallum Issues a Hold Rating on Avid Bioservices (CDMO)December 7, 2024 | markets.businessinsider.comCannell Capital to vote against Avid Biosciences takeoverDecember 2, 2024 | msn.comCDMO Investors Have the Opportunity to Join Investigation of Avid Bioservices, Inc. with the Schall Law FirmDecember 2, 2024 | businesswire.comSee More Avid Bioservices Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Avid Bioservices? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avid Bioservices and other key companies, straight to your email. Email Address About Avid BioservicesAvid Bioservices (NASDAQ:CDMO) operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.View Avid Bioservices ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
